Synopsys pulls full-year guidance, citing new China export restrictions

Synopsys withdrew its full fiscal year guidance following a letter from the U.S. Commerce Department imposing restrictions on sales to China, causing its stock to decline by 3%. The company is assessing the potential impact of the restrictions, which come after CEO Sassine Ghazi acknowledged a slowdown in China during the fiscal second quarter, where Chinese customers accounted for approximately 10% of Synopsys' $1.6 billion in quarterly revenue amid increasing competition and government support for local companies.

Analysis

Synopsys has withdrawn its guidance for the full fiscal year after receiving a letter from the U.S. Commerce Department outlining restrictions on sales of its products in China, an action that precipitated an approximate 3% decline in its stock price. This development occurred shortly after CEO Sassine Ghazi had disputed reports of a sales halt, and the company is now formally assessing the potential impact of this Bureau of Industry and Security (BIS) letter on its business, operating results, and financial condition. China represented a significant market, accounting for roughly 10% of Synopsys' $1.6 billion in revenue during its fiscal second quarter, which concluded on April 30. Ghazi had previously acknowledged a slowdown in China during this quarter, attributing it to the cumulative effects of existing restrictions and a deteriorating macroeconomic climate, noting that these headwinds have strengthened over the past 12 to 18 months. The situation is further complicated by fierce competition within China, where government policies and investments actively favor domestic companies aiming to establish independent chip design capabilities.

Key Decisions for Investors

• Investors should anticipate heightened volatility and potential downward pressure on Synopsys's earnings outlook following the withdrawal of its full fiscal year guidance and the new U.S. restrictions on its sales to China.
• Closely monitor Synopsys's forthcoming assessment of the BIS letter's financial impact, particularly concerning the ~10% revenue exposure to China, and any announced strategic adjustments in response to these regulatory changes.
• Re-evaluate exposure to Synopsys considering the increased risk profile stemming from escalating U.S.-China trade tensions, intensifying competition within China, and the potential for further regulatory actions impacting its operations in this key market.